Japanese Pharmacology & Therapeutics（JPT）
Vol. 36 Suppl. 2 2008
Opening Remarks
M. Hirano
Jpn Pharmacol Ther 2008 36(s2) s95
1．The prediction of the in vivo human hepatic clearance based on the in vitro uptake assay using isolated human hepatocytes
K. Maeda, et al.
Jpn Pharmacol Ther 2008 36(s2) s101-6
2．Investigation of the substrate recognition site of OATP1B1 using chimeric protein expression systems
M. Miyagawa, et al．
Jpn Pharmacol Ther 2008 36(s2) s107-11
3．Sodium butyrate enhances the cell surface expression and the transport capacity of BSEP
T. Kato, et al．
Jpn Pharmacol Ther 2008 36(s2) s113-6
4．4-phenylbutyrate prolongs the half-life of cell-surface-resident BSEP
H. Hayashi, et al．
Jpn Pharmacol Ther 2008 36(s2)s117-9
【Discussion 1～4】
Jpn Pharmacol Ther 2008 36(s2) s121-4
5．Involvement of transporters in the hepatic elimination of glycyrrhizin and the effect of their genetic polymorphisms on its pharmacokinetics
Y. Debori, et al．
Jpn Pharmacol Ther 2008 36(s2) s125-30
6．Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2（BCRP）gene polymorphisms in humans
I. Ieiri, et al．
Jpn Pharmacol Ther 2008 36(s2) s131-4
7．A case of alcoholic liver cirrhosis with alternative ratio of direct and indirect bilirubin
F. Kira, et al．
Jpn Pharmacol Ther 2008 36(s2) s135-40
【Discussion 5～7】
Jpn Pharmacol Ther 2008 36(s2) s141-2
8．Effect of tauroursodeoxycholate on the decreased Mrp2 expression in bile duct-ligated rats
Y. Morisawa, et al．
Jpn Pharmacol Ther 2008 36(s2) s143-5
10．Bile acids promote migration of hepatic stellate cells
T. Ikegami, et al．
Jpn Pharmacol Ther 2008 36(s2) s147-9
【Discussion 8～10】
Jpn Pharmacol Ther 2008 36(s2) s151-3
11．The effect of sphingosine 1-phosphate（S1P）on liver sinusoidal endothelial cells
T. Kitamura, et al．
Jpn Pharmacol Ther 2008 36(s2) s155-7
12．Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress－induced hepatocellular injury
A. Uchiyama, et al．
Jpn Pharmacol Ther 2008 36(s2) s159-64
13．Preventive effects of vitamin K2 on hepatocarcinogenesis in rats
K. Hosho, et al．
Jpn Pharmacol Ther 2008 36(s2) s165
【Discussion 11～13】
Jpn Pharmacol Ther 2008 36(s2) s171-2
14．The association of matrix metalloproteinase-7 gene polymorphisms with liver fibrosis and hepatocarcinogenesis
N. Maeda, et al．
Jpn Pharmacol Ther 2008 36(s2) s173-6
15．Olmesaltan medoxomil in patients with cirrhosis―Effects on liver fifrosis markers―
H. Hidaka, et al．
Jpn Pharmacol Ther 2008 36(s2) s177-80
16．Usefulness of liver stiffness in patients with chronic liver disease
N. Enomoto, et al．
Jpn Pharmacol Ther 2008 36(s2) s181-5
【Discussion 14～16】
Jpn Pharmacol Ther 2008 36(s2) s187-91
17．Effects of advanced glycation end-products and high glucose on hepatocytes
T. Ishitobi, et al．
Jpn Pharmacol Ther 2008 36(s2) s189-92
18．Physiological influence of free fatty acid on Kupffer cell
N. Obara, et al．
Jpn Pharmacol Ther 2008 36(s2) s193-5
19．Effect of pioglitazone on liver regeneration failure following partial hepatectomy in obese KK-Ay mice
T. Aoyama et al．
Jpn Pharmacol Ther 2008 36(s2) s197-9
20．Can FLS-ob mouse be a model for NASH ?
T. Sugihara, et al．
Jpn Pharmacol Ther 2008 36(s2) s201-6
【Discussion 17～20】
Jpn Pharmacol Ther 2008 36(s2) s207-9
21．A proposal of simple scoring system to differentiate nonalcoholic steatohepatitis from nonalcoholic fatty liver disease
Y. Sumida, et al．
Jpn Pharmacol Ther 2008 36(s2) s211-4
22．A simple noninvasive markers of nonalcoholic steatohepatisis
T. Matono, et al．
Jpn Pharmacol Ther 2008 36(s2) s215-9
23．Evaluation of NASH using methods of nuclear medicine
―Analysis of hepatic and splenic uptake―
C. Koreeda, et al．
Jpn Pharmacol Ther 2008 36(s2) s221-4
【Discussion 21～23】
Jpn Pharmacol Ther 2008 36(s2) s225-6
24．Longitudinal analysis of body composition in nonalcoholic fatty liver disease patients
M. Iwasa, et al．
Jpn Pharmacol Ther 2008 36(s2) s227-9
25．Involvement of advanced glycation end products（AGE）in nonalcoholic steatohepatitis（NASH）
H. Hyogo, et al．
Jpn Pharmacol Ther 2008 36(s2) s231-4
26．Fat deposition in multifidus muscle is correlated with visceral fat accumulation in patients with non-alcoholic fatty liver disease
Y. Kitajima, et al．
Jpn Pharmacol Ther 2008 36(s2) s235-7
27．Efficacy of low dose pioglitazone in Japanese patients with nonalcoholic fatty liver disease
R. Yaginuma, et al．
Jpn Pharmacol Ther 2008 36(s2) s239-41
【Discussion 24～27】
Jpn Pharmacol Ther 2008 36(s2) s243-4
Closing Remarks
S. Watanabe
Jpn Pharmacol Ther 2008 36(s2) s245